IE
STOK icon

Israel Englander’s Stoke Therapeutics STOK Stock Holding History

Israel Englander’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,000
Closed -$1.3M – 6379
2026
Q1 		$1.3M Buy
+40,000
New +$1.31M ﹤0.01% 4186

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's STOK Position: Q2 2026 in Review

Israel Englander reduced its Stoke Therapeutics (STOK) stake by 45% in Q2 2026, selling an estimated $6.78M and leaving 261,028 shares worth $8.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2452.

Israel Englander first reported a position in STOK in Q2 2019 and has held it in 25 quarters since. The position peaked at $16.1M in Q2 2019. 196 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Israel Englander held 261,028 shares of Stoke Therapeutics worth $8.54M as of Q2 2026.
  • Israel Englander sold 211,113 Stoke Therapeutics shares in Q2 2026, an estimated $6.78M.
  • Stoke Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2452 holding.
  • Israel Englander first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • Israel Englander's Stoke Therapeutics position peaked at $16.1M in Q2 2019.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.